Lipid-based nanoparticles for cancer treatment

Obeid, Mohammad A.; Tate, Rothwelle J.; Mullen, Alexander B.; Ferro, Valerie A.

doi:10.1016/b978-0-12-813687-4.00008-6

Cited by 48 publications

(27 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To evaluate the cytotoxicity of the CN, B16-F10 cells were seeded into a 96-well plate at a density of 1x10 4 per well in 100µl RPMI 1640 medium supplemented with 10% Differences were considered statistically significant for p values < 0.05.…”

Section: Cell Viability Assaymentioning

confidence: 99%

“…Therefore, therapeutic application of siRNA requires the use of an efficient delivery vehicle that can carry, protect, and efficiently deliver siRNA into target cells [3]. In this regard, lipidbased nanoparticles, including liposomes, have been widely investigated as possible siRNA carriers because of their advantages such as high loading efficiency and biocompatibility [4,5]. Through their membrane bilayer structure, lipid nanoparticles can protect siRNA that is embedded in the aqueous core or adsorbed on the surface of the nanoparticles [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Proof of concept studies for siRNA delivery by nonionic surfactant vesicles: in vitro and in vivo evaluation of protein knockdown

Obeid

Dufès

Somani

et al. 2019

Journal of Liposome Research

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Cell Viability Assaymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Proof of concept studies for siRNA delivery by nonionic surfactant vesicles: in vitro and in vivo evaluation of protein knockdown

Obeid

Dufès

Somani

et al. 2019

Journal of Liposome Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the US, 22,240 women were diagnosed with ovarian cancer in 2018, although it only accounts for a small percentage of incidence in woman compared to other types of cancer. Nevertheless, it has a high death rate as it is hard to detect at an early stage and therefore patients are usually diagnosed at its advanced stages (2,3).…”

Section: Introductionmentioning

confidence: 99%

Niosome-encapsulated balanocarpol: compound isolation, characterisation, and cytotoxicity evaluation against human breast and ovarian cancer cell lines

et al. 2020

View full text Add to dashboard Cite

Natural products have been successfully used for treating various ailments since ancient times and currently there are several natural product based anti-cancer agents used as the main therapy to treat cancer patients or as a complimentary treatment to chemotherapy or radiation.Balanocarpol, which is a promising natural product that has been isolated from Hopea dryobalanoides, has been studied as a potential anticancer agent but its application is limited due to its high toxicity, low water solubility, and poor bioavailablity. Therefore, the aim of this study was to improve the balanocarpol characteristics and improve its anticancer activity through its encapsulation into a bilayer structure of a lipid-based nanoparticle drug delivery system where the application of nanotechnology can help in improving such limitations of balanocarpol. The compound first was extracted and isolated from H. dryobalanoides.Niosome nanoparticles composed of span 80 (SP80) and cholesterol were formulated through innovative microfluidic mixing method for the encapsulation and delivery of balanocarpol. The prepared particles were spherical, small, and uniform with an average particles size and polydispersity index ~ 175 nm and 0.088 respectively. The encapsulation of balanocarpol into the SP80 niosomes resulted in an encapsulation efficiency of ~ 40%. The niosomes formulation loaded with balanocarpol showed superior anticancer effect over the free compound when tested in vitro on human ovarian carcinoma (A2780) and human breast carcinoma (ZR-75-1). This is the first study that report the use of SP80 niosomes for successful encapsulation and delivery of balanocarpol into cancer cells.

show abstract

“…The main advantages of these nanoparticles are that they can be loaded with hydrophilic and hydrophobic drugs, can be surface-modified, lend themselves to site-specific targeting, offer control of drug release, and exhibit low in vivo toxicity. However, there remain some disadvantages, such as drug expulsion after polymorphic transition of the lipid from the nanocarrier matrix in the storage period and low loading capacity [32].…”

Section: Lipid-based Nanoparticlesmentioning

confidence: 99%

Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment

et al. 2019

View full text Add to dashboard Cite

Many therapeutically active molecules are non-soluble in aqueous systems, chemically and biologically fragile or present severe side effects. Lipid-based nanoparticle (LBNP) systems represent one of the most promising colloidal carriers for bioactive organic molecules. Their current application in oncology has revolutionized cancer treatment by improving the antitumor activity of several chemotherapeutic agents. LBNPs advantages include high temporal and thermal stability, high loading capacity, ease of preparation, low production costs, and large-scale industrial production since they can be prepared from natural sources. Moreover, the association of chemotherapeutic agents with lipid nanoparticles reduces active therapeutic dose and toxicity, decreases drug resistance and increases drug levels in tumor tissue by decreasing them in healthy tissue. LBNPs have been extensively assayed in in vitro cancer therapy but also in vivo, with promising results in some clinical trials. This review summarizes the types of LBNPs that have been developed in recent years and the main results when applied in cancer treatment, including essential assays in patients.

show abstract

Lipid-based nanoparticles for cancer treatment

Cited by 48 publications

References 169 publications

Proof of concept studies for siRNA delivery by nonionic surfactant vesicles: in vitro and in vivo evaluation of protein knockdown

Proof of concept studies for siRNA delivery by nonionic surfactant vesicles: in vitro and in vivo evaluation of protein knockdown

Niosome-encapsulated balanocarpol: compound isolation, characterisation, and cytotoxicity evaluation against human breast and ovarian cancer cell lines

Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment

Contact Info

Product

Resources

About